Diagnostic shift from later-stage to earlier-stage disease may have implications for evaluation of treatments and mortality outcomes

Predictive models based on comparison of serum metabolomic patterns for patients at time of lung cancer diagnosis and matched controls

National five-year survival rate for lung cancer has increased to 23.7 percent, but disparities persist for people of color